Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | FLT1 | P17948 | 3/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876110 | 0.80 | NPC1 (0.56) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3109928 | 0.80 | JAK2 (0.52) | KDRNPC1RAB9AJAK2JAK1 | |
| SCHEMBL4034467 | 0.79 | NPC1 (0.55) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL6543870 | 0.79 | KIT (0.63) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4034472 | 0.77 | NPC1 (0.52) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL6785680 | 0.77 | MLLT1 (0.42) | KDRJAK2JAK1FLT1 | |
| SCHEMBL4042755 | 0.77 | NPC1 (0.52) | KDRNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL5857039 | 0.76 | JAK2 (0.72) | KDRNPC1RAB9AJAK2JAK1 | |
| SCHEMBL5900863 | 0.76 | RXFP1 (0.53) | KDRFLT1 | |
| SCHEMBL14483974 | 0.76 | ABCG2 (0.56) | NPC1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | SCHERING AG (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | KDR, FLT1, FLT4 | KDR 1/4885NPC1 4565/4885RAB9A 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.